Radiopharm Theranostics Closes US$4.1M Direct Offering
Radiopharm Theranostics Limited announced the closing of its registered direct offering, raising approximately US$4.1 million in gross proceeds. The company issued 1,281,646 American Depositary Shares (ADSs) at US$3.16 per ADS and concurrently issued unregistered warrants to purchase an equal number of ADSs at an exercise price of US$3.79, expiring in July 2029, subject to shareholder approval. Additionally, the company secured A$6.7 million (US$4.7 million) from an Australian private placement and plans a Share Purchase Plan to raise up to A$6 million (US$4.2 million), both also subject to shareholder approval. The capital raised will fund the RAD101 registrational Phase 3 study, RAD 204 dose escalation, other therapeutic programs, and general corporate purposes.
Key Highlights
- Closed a registered direct offering, raising aggregate gross proceeds of approximately US$4.1 million.
- Issued 1,281,646 American Depositary Shares (ADSs) at an offering price of US$3.16 per ADS.
- Issued unregistered warrants to purchase up to 1,281,646 ADSs at an exercise price of US$3.79 per ADS.
- Warrants will be exercisable after shareholder approval and expire on July 31, 2029.
- Secured A$6.7 million (US$4.7 million) from an Australian private placement, subject to shareholder approval.
- Plans a Share Purchase Plan to raise up to an additional A$6 million (US$4.2 million), subject to shareholder approval.
- Funds will be used for RAD101 Phase 3 study, RAD 204 dose escalation, other therapeutic programs, and corporate purposes.
- Shareholder approvals for various issuances are expected at an EGM around September 11, 2026.
Price Impact
More from RADX
Radiopharm Theranostics RAD101 Phase 3 Trial Set for 1Q27; RAD301 Data Positive
Radiopharm Theranostics Seeks Approval for $18.5M Capital Raise
Radiopharm Theranostics Reports Positive RAD 101 Phase 2b Results; Raises $12.5M
More in Corporate Action